Background: About one third of cancer patients suffers from a psychiatric disorder. However, only few studies feature long-term assessment of psychiatric disease in cancer patients, covering a broad range of diagnoses, and employing high-quality instruments. Patients and Methods: A total of 62 patients underwent assessments during a 3-year follow-up period after initial cancer diagnosis. The Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) was used to measure psychiatric morbidity at baseline (t1) and 2 follow-up assessments (t2 and t3). Follow-up assessments took place between 6 and 18 months (t2) and between 24 and 36 months (t3) after baseline measurement. Results: At t1, at least one DSM-IV diagnosis was found in 29% of the patients. During follow-up, the frequency of psychiatric morbidity increased to 36% at t2 and 44% at t3. New occurrence of psychiatric disease during follow-up was 18% at t2 and 38% at t3. Conclusion: Persistence and number of newly diagnosed psychiatric disorders during the first 3 years after cancer treatment should be considered in the treatment of cancer patients, especially in individuals with according predictive factors.

Keywords:
Psychiatric morbidity, DSM-IV, Long-term course
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.